Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with ...

The VERIFY trial explores rusfertide to manage polycythemia vera without causing iron deficiency symptoms, Dr. Aaron Gerds explained.

For patients with a rare type of blood cancer, treatment might finally be coming out of the Dark Ages. People with the ...

The novel drug reduces the need for burdensome phlebotomy and also addresses fatigue, thereby improving quality of life for ...

the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and polycythemia vera must be excluded. The present case and others in the literature indicate that the ...

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet ...

If you’re a fan of comedies, there’s a good chance you’ve come across the multitalented filmmaker Todd Strauss-Schulson.

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a ...

Rusfertide (Protagonist Therapeutics/Takeda Pharmaceuticals) — administered as a once-weekly subcutaneous injection — also ...

The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among ...

Adding rusfertide to standard care can reduce the need for phlebotomy and improve symptoms in patients with polycythemia vera who require frequent phlebotomies, data suggest.